Evaluation of the function of human invariant NKT cells from cancer patients using α-galactosylceramide-loaded murine dendritic cells

Journal of Immunology

Volumn 177, Issue 5, 2006, Pages 3484-3492

  Shimizu, Kanako ^a   Hidaka, Michihiro ^b   Kadowaki, Norimitsu ^c   Makita, Noriko ^a   Konishi, Naoko ^a   Fujimoto, Koji ^b   Uchiyama, Takashi ^c   Kawano, Fumio ^b   Taniguchi, Masaru ^a   Fujii, Shin Ichiro ^a  

^a Institute of Physical and Chemical Research   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; BETA 2 MICROGLOBULIN; CD14 ANTIGEN; CD1D ANTIGEN; GAMMA INTERFERON; IMATINIB;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL FUNCTION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOREGULATION; MONOCYTE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE ACTIVATION;

EID: 33747805272     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.5.3484     Document Type: Article

References (55)

1. Taniguchi, M., M. Harada, S. Kojo, T. Nakayama, and H. Wakao. 2003. The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 21: 483-513.
2. Fujii, S., K. Shimizu, C. Smith, L. Bonifaz, and R. M. Steinman. 2003. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a co-administered protein. J. Exp. Med. 198: 267-279.
3. Fujii, S., K. Liu, C. Smith, A. J. Bonito, and R. M. Steinman. 2004. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J. Exp. Med. 199: 1607-1618.
4. Kronenberg, M. 2005. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 23: 877-900.
5. Tahir, S. M., O. Cheng, A. Shaulov, Y. Koezuka, G. J. Bubley, S. B. Wilson, S. P. Balk, and M. A. Exley. 2001. Loss of IFN-γ production by invariant NK T cells in advanced cancer. J. Immunol. 167: 4046-4050.
6. + natural killer T cells of healthy volunteers and cancer patients using α-galactosylceramide-loaded and environmentally instructed dendritic cells. Cancer Res. 63: 4101-4106.
7. Dhodapkar, M. V., M. D. Geller, D. H. Chang, K. Shimizu, S. Fujii, K. M. Dhodapkar, and J. Krasovsky. 2003. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med. 197: 1667-1676.
8. + NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int. J. Cancer. 116: 87-93.
9. Fujii, S., K. Shimizu, M. Kronenberg, and R. M. Steinman. 2002. Prolonged interferon-γ producing NKT response induced with α- galactosylceramide-loaded dendritic cells. Nat. Immunol. 3: 867-874.
10. + NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103: 383-389.
11. Ishikawa, A., S. Motohashi, E. Ishikawa, H. Fuchida, K. Higashino, M. Otsuji, T. Iizasa, T. Nakayama, M. Taniguchi, and T. Fujisawa. 2005. A phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 11: 1910-1917.
12. Chang, D. H., K. Osman, J. Connolly, A. Kukreja, J. Krasovsky, M. Pack, A. Hutchinson, M. Geller, N. Liu, R. Annable, et al. 2005. Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 201: 1503-1517.
13. + natural killer T cells using α-galactosyl ceramide-pulsed dendritic cells. J. Immunol. Meth. 272: 147-159.
14. Pollard, J. W. 2004. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4: 71-78.
15. Yang, L., and D. P. Carbone. 2004. Tumor-host immune interactions and dendritic cell dysfunction. Adv. Cancer Res. 92: 13-27.
16. Fujii, S., K. Shimizu, K. Fujimoto, T. Kiyokawa, T. Shimomura, M. Kinoshita, and F. Kawano. 1999. Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation. Jpn. J. Cancer Res. 90: 1117-1129.
17. Onishi, H., T. Morisaki, E. Baba, H. Kuga, H. Kuroki, K. Matsumoto, M. Tanaka, and M. Katano. 2002. Dysfunctional and short-lived subsets in monocyte-derived dendritic cells from patients with advanced cancer. Clin. Immunol. 105: 286-295.
18. Eisendle, K., A. Lang, B. Eibl, D. Nachbaur, H. Glassl, M. Fiegl, J. Thaler, and G. Gastl. 2003. Phenotypic and functional deficiencies of leukaemic dendritic cells from patients with chronic myeloid leukaemia. Br. J. Haematol. 120: 63-73.
19. Della Bella, S., M. Gennaro, M. Vaccari, C. Ferraris, S. Nicola, A. Riva, M. Clerici, M. Greco, and M. L. Villa. 2003. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br. J. Cancer 89: 1463-1472.
20. Kawano, T., T. Nakayama, N. Kamada, Y. Kaneko, M. Harada, N. Ogura, Y. Akutsu, S. Motohashi, T. Iizasa, H. Endo, et al. 1999. Antitumor cytotoxicity mediated by ligand-activated human Vα24 NKT cells. Cancer Res. 59: 5102-5105.
21. Davodeau, F., M. A. Peyrat, A. Necker, R. Dominici, F. Blanchard, C. Leget, J. Gaschet, P. Costa, Y. Jacques, A. Godard, et al. 1997. Close phenotypic and functional similarities between human and murine αβ T cells expressing invariant TCR α-chains. J. Immunol. 158: 5603-5611.
22. Brossay, L., M. Chioda, N. Burdin, Y. Koezuka, G. Casorati, P. Dellabona, and M. Kronenberg. 1998. CD1d-mediated recognition of an α- galactosylceramide by natural killer T Cells is highly conserved through mammalian evolution. J. Exp. Med. 188: 1521-1528.
23. - T cells in transgenic mice. J. Immunol. 170: 2390-2398.
24. Zhou, D., J. Mattner, C. Cantu 3rd, N. Schrantz, N. Yin, Y. Gao, Y. Sagiv, K. Hudspeth, Y. P. Wu, T. Yamashita, et al. 2004. Lysosomal glycosphingolipid recognition by NKT cells. Science 306: 1786-1789.
25. Schmieg, J., G. Yang, R. W. Franck, and M. Tsuji. 2003. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand α-galactosylceramide. J. Exp. Med. 198: 1631-1641.
26. Wu, D. Y., N. H. Segal, S. Sidobre, M. Kronenberg, and P. B. Chapman. 2003. Cross-presentation of disialoganglioside GD3 to natural killer T cells. J. Exp. Med. 198: 173-181.
27. O'Brien, S., A. Tefferi, and P. Valent. 2004. Chronic myelogenous leukemia and myeloproliferative disease. Hematology (Am. Soc. Hematol. Educ. Program): 146-162.
28. Mohty, M., D. Jarrossay, M. Lafage-Pochitaloff, C. Zandotti, F. Briere, X. N. de Lamballeri, D. Isnardon, D. Sainty, D. Olive, and B. Gaugler. 2001. Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood 98: 3750-3756.
29. Dong, R., K. Cwynarski, A. Entwistle, F. Marelli-Berg, F. Dazzi, E. Simpson, J. M. Goldman, J. V. Melo, R. I. Lechler, I. Bellantuono, et al. 2003. Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. Blood 101: 3560-3567.
30. Druker, B. J., S. Tamura, E. Buchdunger, S. Ohno, G. M. Segal, S. Fanning, J. Zimmermann, and N. B. Lydon. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2: 561-566.
31. Deininger, M., E. Buchdunger, and B. J. Druker. 2005. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105: 2640-2653.
32. Dietz, A. B., L. Souan, G. J. Knutson, P. A. Bulur, M. R. Litzow, and S. Vuk-Pavlovic. 2004. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 104: 1094-1099.
33. Cwynarski, K., R. Laylor, E. Macchiarulo, J. Goldman, G. Lombardi, J. V. Melo, and F. Dazzi. 2004. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 18: 1332-1339.
34. Mohty, M., E. Jourdan, N. B. Mami, N. Vey, G. Damaj, D. Blaise, D. Isnardon, D. Olive, and B. Gaugler. 2004. Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. Blood 103: 4666-4668.
35. Dewar, A. L., A. C. Cambareri, A. C. Zannettino, B. L. Miller, K. V. Doherty, T. P. Hughes, and A. B. Lyons. 2005. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 105: 3127-3132.
36. + peripheral blood progenitor cells. Blood 103: 538-544.
37. Taieb, J., K. Maruyama, C. Borg, M. Terme, and L. Zitvogel. 2004. Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. Blood 103: 1966-1967.
38. Cebo, C., S. Da Rocha, S. Wittnebel, A. G. Turhan, J. Abdelali, S. Caillat-Zucman, J. H. Bourhis, S. Chouaib, and A. Caignard. 2006. The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GMI expression, and synapse formation. J. Immunol. 176: 864-872.
39. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176: 1693-1702.
40. + T cells in vitro. Hum. Immunol. 61: 357-365.
41. + NKT cells activated by α-glycosylceramide-pulsed monocyte-derived dendritic cells. J. Immunol. 164: 4458-4464.
42. Metelitsa, L. S., O. V. Naidenko, A. Kant, H. W. Wu, M. J. Loza, B. Perussia, M. Kronenberg, and R. C. Seeger. 2001. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J. Immunol. 167: 3114-3122.
43. Lurquin, C., B. Lethe, E. De Plaen, V. Corbiere, I. Theate, N. van Baren, P. G. Coulie, and T. Boon. 2005. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J. Exp. Med. 201: 249-257.
44. Germeau, C., W. Ma, F. Schiavetti, C. Lurquin, E. Henry, N. Vigneron, F. Brasseur, B. Lethe, E. De Plaen, T. Velu, et al. 2005. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J. Exp. Med. 201: 241-248.
45. Giaccone, G., C. J. Punt, Y. Ando, R. Ruijter, N. Nishi, M. Peters, B. M. von Blomberg, R. J. Scheper, H. J. van der Vliet, A. J. van den Eertwegh, et al. 2002. A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 8: 3702-3709.
46. Dhodapkar, K. M., B. Cirignano, F. Chamian, D. Zagzag, D. C. Miller, J. L. Finlay, and R. M. Steinman. 2004. Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion. Int. J. Cancer 109: 893-899.
47. + NKT cell numbers decrease in patients with haematopoietic malignancy. Leuk. Res. 29: 147-152.
48. Shen, Z., G. Reznikoff, G. Droanoff, and K. L. Rock. 1997. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J. Immunol. 158: 2723-2730.
49. Foti, M., F. Granucci, D. Aggujaro, E. Liboi, W. Luini, S. Minardi, A. Mantovani, S. Sozzani, and P. Ricciardi-Castagnoli. 1999. Upon dendritic cell (DC) activation chemokines and chemokine receptor expression are rapidly regulated for recruitment and maintenance of DC at the inflammatory site. Int. Immunol. 11: 979-986.
50. Hochhaus, A., S. Kreil, A. S. Corbin, P. La Rosee, M. C. Muller, T. Lahaye, B. Hanfstein, C. Schoch, N. C. Cross, U. Berger, et al. 2002. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16: 2190-2196.
51. Hughes, T. P., J. Kaeda, S. Branford, Z. Rudzki, A. Hochhaus, M. L. Hensley, I. Gathmann, A. E. Bolton, I. C. van Hoomissen, J. M. Goldman, and J. P. Radich. 2003. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349: 1423-1432.
52. Bhatia, R., M. Holtz, N. Niu, R. Gray, D. S. Snyder, C. L. Sawyers, D. A. Arber, M. L. Slovak, and S. J. Forman. 2003. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101: 4701-4707.
53. Michor, F., T. P. Hughes, Y. Iwasa, S. Branford, N. P. Shah, C. L. Sawyers, and M. A. Nowak. 2005. Dynamics of chronic myeloid leukaemia. Nature 435: 1267-1270.
54. Bocchia, M., S. Gentili, E. Abruzzese, A. Fanelli, F. Iuliano, A. Tabilio, M. Amabile, F. Forconi, A. Gozzetti, D. Raspadori, et al. 2005. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365: 657-662.
55. Li, Z., Y. Qiao, B. Liu, E. J. Laska, P. Chakravarthi, J. M. Kulko, R. D. Bona, M. Fang, U. Hegde, V. Moyo, et al. 2005. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin. Cancer Res. 11: 4460-4468.